Helicobacter pylori infection. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
Conditions
Interventions
Intervention 1: Intervention group: Nanocurcumin capsule 40 mg every 8 hours (Exir Nano Sina Company) + Levofloxacin 500 mg daily + Omeprazole 20 mg every 12 hours + Amoxicillin 1 gr every 12 hours fo
Sponsors
Birjand University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Having informed consent to enter the study People aged 18 to 70 years with digestive symptoms such as dyspepsia, nausea, vomiting and epigastric burning Any person who does not have any of the exclusion criteria
Exclusion criteria
Exclusion criteria: History of anti-Helicobacter pylori treatment Taking antibiotics Acute gastrointestinal bleeding Proton pump inhibitor use in the last month Pregnancy or breastfeeding Allergy to turmeric and ginger family Known cancers including stomach People with HIV Recent surgeries Alcohol consumption and the presence of systemic diseases such as cardiovascular diseases and diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hong Kong dyspepsia index. Timepoint: before the intervention, immediately after the intervention and one month after the end of the intervention. Method of measurement: Hong Kong dyspepsia index.;Helicobacter pylori eradication rate. Timepoint: One month after treatment. Method of measurement: Stool antigen test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of clinical symptoms (dyspepsia, nausea, vomiting and epigastric burning) in the intervention and placebo groups. Timepoint: The beginning and end of the study. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadali mahdiabadi
Birjand University of Medical Sciences
Outcome results
None listed